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Résumé en
anglais
Several convergent destructive mechanisms such as oxidative stress, alveolar cell
apoptosis, extracellular matrix proteolysis and chronic inflammation contribute to
chronic obstructive pulmonary disease (COPD) development. Evidence suggests
that oxidative stress contributes to the pathophysiology of COPD, particularly
during exacerbations. Nuclear factor erythroid-2-related factor 2 (NRF2), a
transcription factor expressed predominantly in epithelium and alveolar
macrophages, has an essential protective role in the lungs through the activation of
antioxidant response element-regulated antioxidant and cytoprotective genes.
Animal models and human studies have identified NRF2 and several NRF2 target
genes as a protective system against inflammation and oxidative stress from
cigarette smoke, a major causative factor in COPD development. Hence, NRF2
































Publié sur Okina (http://okina.univ-angers.fr)
